Nachrichten

bioMérieux receives De Novo FDA Authorization for its BIOFIRE® Joint Infection (JI) Panel

04 Mai, 2022

Joint infections (“septic arthritis”) are serious infections involving either native  or prosthetic joints. They are medical emergencies which can occur at all ages, and can lead to functional joint impairment, long-lasting disability, and may even be life-threatening. The number of prosthetic...

z.B. 12/21/2024
z.B. 12/21/2024

CE marking of bioMérieux serology tests for SARS-CoV-2 on VIDAS®

27 Mai, 2020

bioMérieux serology tests for SARS-CoV-2 on VIDAS® undergo validation preceding imminent launch 

06 Mai, 2020

BIOFIRE® Respiratory Panel 2.1 (RP2.1) with SARS-CoV-2 obtains FDA Emergency Use Authorization 

04 Mai, 2020

First-Quarter 2020 Business Review

16 April, 2020

bioMérieux receives Emergency Use Authorization for BIOFIRE® COVID-19 test

24 März, 2020

First of 3 diagnostic tests for  SARS-CoV-2 coronavirus available from bioMérieux

11 März, 2020

bioMérieux – 2019 Financial Results

14 Januar, 2020

bioMérieux submits enhanced BIOFIRE® BCID2 Panel for FDA clearance

14 Januar, 2020

bioMérieux, a world leader in the field of in vitro diagnostics, announces that BioFire Diagnostics, its molecular biology affiliate, has submitted to the Food and Drug Administration for 510(k) clearance of the BIOFIRE® Blood Culture Identification 2 (BCID2) Panel. The BIOFIRE® BCID2 Panel includes several additional pathogens, an expanded list of antimicrobial resistance genes, and many revised targets compared to the existing BIOFIRE® BCID Panel.d about 9,800.

bioMérieux – Third-Quarter 2019 Business Review

22 Oktober, 2019

bioMérieux – First-Half 2019 Results

04 September, 2019

Pioneering Diagnostics